Search results for

By their nature, life science companies are among the more IP-dependent businesses in the corporate world. Any transactions, therefore, will require a more thorough due diligence than is the norm. Paul M Booth and Leslie Mooi outline 10 things you should know about such a company before deciding to invest in, or acquire, it

According to Regulation 1768/92/EEC supplementary protection certificates (SPCs) can be granted for novel medicines. They are intended to compensate for the reduced effective lifetime of patents covering such medicines.

On their face, transfer prices can have dangerous implications for potential damages claims in infringement cases. Phillip Beutel, Bryan Ray and Steven Schwartz outline what in-house counsel need to know to avoid pitfalls

New rules on criminal thresholds should make it easier for prosecutors to bring charges against IP infringers. But as the authorities struggle to manage a mounting workload, IP owners should consider taking the law into their own hands and launching private criminal prosecutions, explains Gordon Gao

The past year has seen important changes in the EU. It grew from 15 member states to 25 and, for the pharmaceutical industry, many new laws entered into force, were enacted, or were proposed. Linda Horton reviews the developments

Japanese businesses are increasingly turning to litigation to resolve their IP disputes. Lloyd Parker, Andrew Cobden and Yukihiro Otani spoke to Japanese managers to find out what lies behind the trend

On March 1 2005, the China Internet Network Information Center (CNNIC) issued an interpretation on its Domain Name Dispute Resolution Policy (the Interpretation) to clarify three definitions. The Interpretation took immediate effect.

In order to promote pharmaceutical research within the European Community and to keep the pharmaceutical industry from relocating to countries which offer better protection, EC Regulation Number 1768/92 for supplementary protection certificates (SPCs) was created. SPCs in the Netherlands are also governed by Regulation Number 1768/92. This is a clear and simple regulation which was meant to extend the life of a patent as far as it covered a medicinal product which had received regulatory approval and which should have led to harmonized SPC legislation in the European Community.

Emma Barraclough, Hong Kong

The scope and importance of discovery during US patent trials cannot be underestimated. Jack Griem explains how the process works, and highlights the best way to get the most of the system